The data mining indicated that the primary SOCs for IGF-1R monoclonal antibody were gastrointestinal disorders, and ear and labyrinth disorders, and general disorders and administration site conditions, which was consistent with the primary adverse reactions listed in the instruction. This evidence concerns the gene IGF1R and digestive system disorder.